Table of Contents Table of Contents
Previous Page  192 / 238 Next Page
Information
Show Menu
Previous Page 192 / 238 Next Page
Page Background

192

29

th

CONGRESS OF THE ESPU

13:14–13:19

S26-6 (LO)

BOTULINUM TOXIN TYPE-A INJECTIONS

FOR THE TREATMENT OF CONTINENT CATHETERIZABLE

RESERVOIR MUSCULARIS OVERACTIVITY IN PEDIATRIC

PATIENTS

Luis SIERRA, Laia SABIOTTE, Erika LLORENS and Anna BUJONS

Fundació Puigvert, Pediatric urology Unit, Barcelona, SPAIN

PURPOSE

Continent catheterizable reservoirs can exhibit complications such as high pressures and involun-

tary unit contractions. The use of onabotulinum toxin-A injections could be a treatment to explore.

The purpose is to evaluate the efficacy and safety of intravesical injection of onabotulinumtoxinA

(BOTOX) as a treatment in the management of overactive bladder in patients with continent cath-

eterizable reservoirs.

MATERIAL AND METHODS

A prospective study was carried between 2013–2016 to evaluate the efficacy of botulinum toxin

treatment in pediatric patients with mean age of 14 years old (R 8–16) with muscularis overactivity

in continent catheterizable reservoirs after failing maximal doses of oral anticholinergic medications.

Urodynamic studies demonstrated phasic neobladder overactivity: 95 mL (up to 40 cm H2O) and

173 mL (up to 83 cm H2O with leakage).

These patients underwent reservoir injections under general anesthesia via appendicovesicostomy.

The initial dose used was 200 units and was increased to 300 units in 20 separate injection sites to

improve results and durability.

RESULTS

11 injections of BOTOX were performed in 6 patients. All patients improved their incontinence and

urgence after BOTOX. Postinjection urodymamic studies showed normal filling with improvement

of overactivity bladder. Mean time to relapse of symptoms after injection of BOTOX was 8 months

(R6–12). There were no complications in any cases. Mean time to reinjection of botox was

14 months (R9–18). Average follow-up time 48 months (R 12–36).

CONCLUSIONS

Intravesical injection of BOTOX may be considered as a treatment option for overactive symptoms

in patients with continent catheterizable reservoirs, although further studies are needed to verify the

complications and long-term outcomes of this procedure.